In this context, studies investigating the potential of interleukin- (IL-) 4- and IL-10-mediated immunomodulation of T1D through individual or combined administration have shown that this is a new field to be explored [16–19]. The gene discussed is IL10; the disease is type 1 diabetes mellitus.